ARIAD Pharmaceuticals Inc logo

ARIA - ARIAD Pharmaceuticals Inc News Story

$23.99 0.0  0.0%

Last Trade - 15/02/17

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £135.1m
Position in Universe th / 6851

Japan's Takeda to buy U.S. cancer drug maker Ariad in $5.2 bln deal

Mon 9th January, 2017 1:10pm
Jan 9 (Reuters) - Japan's Takeda Pharmaceutical Co Ltd 
 4502.T  said on Monday it would acquire cancer drug maker Ariad 
Pharmaceuticals Inc  ARIA.O  in a deal valued at $5.20 billion. 
    Under the deal, Takeda will pay $24 in cash for each Ariad 
share, a premium of about 75 percent to its Friday close. 
 urn:newsml:reuters.com:*:nBw5gCC56a 
    The transaction, which has been approved unanimously by the 
boards of both companies, is expected to close by the end of 
February. 
 
 (Reporting by Natalie Grover in Bengaluru; Editing by Shounak 
Dasgupta) 
 ((natalie.grover@thomsonreuters.com)(;)(within U.S. +1 646 223 
8780, outside U.S. +91 99 1694 7070)(; Reuters 
Messaging:)(natalie.grover.thomsonreuters.com@reuters.net)) 
 
Keywords: ARIAD PHARM M&A/TAKEDA PHARMA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.